Literature DB >> 2536062

Signaling through T lymphocyte surface proteins, TCR/CD3 and CD28, activates the HIV-1 long terminal repeat.

S E Tong-Starkesen1, P A Luciw, B M Peterlin.   

Abstract

The state of T cell activation and proliferation controls HIV-1 replication and gene expression. Previously, we demonstrated that the administration of PHA and PMA to the human T cell line Jurkat activates the HIV-1 enhancer, which is composed of two nuclear factor kappa B (NF kappa B) binding sites. Here, we show that PMA alone is sufficient for this effect. In addition, activation of T cells through the surface proteins TCR/CD3 and CD28 increased gene expression directed by the HIV-1 long terminal repeat (LTR) to the same extent as PMA. Analysis of 5' deletions in the LTR revealed that the NF kappa B binding sites and sequences in the upstream U3 region are required for this response. Whereas cyclosporin A did not inhibit the effect of PMA, it reduced the effects of agonists to TCR/CD3 and CD28 on the LTR. H7, an inhibitor of protein kinase C (PKC), blocked the effects of all stimuli. Thus, PMA activates the NF kappa B sites through a PKC-dependent pathway while ligands to TCR/CD3 and CD28 activate the LTR through a cyclosporin A-sensitive, PKC-dependent pathway of T cell activation. We conclude that mechanisms involved in the expression of IL-2 and the alpha-chain of the IL-2R alpha genes also play a role in the regulation of HIV-1. Physiologic stimuli can activate HIV-1 gene expression; agents that block T cell activation also inhibit activation of the LTR. These observations might serve as a model for the regulation of HIV-1 gene expression in peripheral blood T cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536062

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  TCR-independent CD28-mediated gene expression in peripheral blood lymphocytes from donors chronically infected with HIV-1.

Authors:  J G Wong; M D Smithgall; O K Haffar
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1.

Authors:  D M Markovitz; M C Hannibal; M J Smith; R Cossman; G J Nabel
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Authors:  Frank Wolschendorf; Alberto Bosque; Takao Shishido; Alexandra Duverger; Jennifer Jones; Vicente Planelles; Olaf Kutsch
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 4.  Is TNF involved in the progression of AIDS?

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto
Journal:  Virus Genes       Date:  1990-07       Impact factor: 2.332

5.  Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.

Authors:  Anjum S Kaka; Donald R Shaffer; Ryan Hartmaier; Ryan Hartmeier; Ann M Leen; An Lu; Adham Bear; Cliona M Rooney; Aaron E Foster
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

6.  Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells.

Authors:  R G Bryan; Y Li; J H Lai; M Van; N R Rice; R R Rich; T H Tan
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4.

Authors:  M Benkirane; H Schmid-Antomarchi; D R Littman; M Hirn; B Rossi; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Infection with the intracellular protozoan parasite Theileria parva induces constitutively high levels of NF-kappa B in bovine T lymphocytes.

Authors:  V Ivanov; B Stein; I Baumann; D A Dobbelaere; P Herrlich; R O Williams
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

Review 9.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

10.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.